Business / Finance

RSS

Valeant divests generic Benzaclin and Efudex to Mylan

Valeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc..

6 Feb 2012

HCA fourth quarter revenues increase 8.5% to $7.769 billion

HCA Holdings, Inc. today announced financial and operating results for the year and fourth quarter ended December 31, 2011. HCA also today announced that its Board of Directors approved a special cash dividend of $2.00 per share to be paid to shareholders of record as of February 16, 2012 with a payment date of February 29, 2012.

6 Feb 2012

BioMedGPS launches new business intelligence service for life sciences industry

BioMedGPS, the leader in healthcare business intelligence and competitive metrics, announces the launch of FastTRAK B.I., a new business intelligence service designed specifically for the life science industry.

6 Feb 2012

EntreMed receives $9.3 million in strategic financing

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received approximately $9.3 million in strategic financing, as previously announced on January 23, 2012.

6 Feb 2012

Humana fourth quarter consolidated revenues increase 9% to $9.06B

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended December 31, 2011 (4Q11) of $1.20, compared to $0.63 per share for the quarter ended December 31, 2010.

6 Feb 2012

MSL becomes a key link between pharmaceutical industry and stakeholders

Medical Science Liaisons have become a key link between the pharmaceutical industry and key stakeholders such as thought leaders that drive marketplace success. And the role of MSLs will grow even more in the coming years as the pharmaceutical industry relies on them to build relationships across a diverse set of customers.

4 Feb 2012

Medical Properties Trust prices $200 million public offering

Medical Properties Trust, Inc. announced today that the previously announced public offering of $200 million aggregate principal amount of senior notes due 2022 by its operating partnership, MPT Operating Partnership, L.P., a Delaware limited partnership, and MPT Finance Corporation, a Delaware corporation and wholly owned subsidiary of the Operating Partnership, priced today with a coupon of 6.375%, at an issue price of 100%.

3 Feb 2012

Sirona first quarter revenue increases 9.5% to $258.1 million

Sirona, the dental technology leader, today announced its financial results for the quarter ended December 31, 2011.

3 Feb 2012

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards.

3 Feb 2012

The Mann Group and MannKind enter stock purchase agreement

MannKind Corporation today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.

3 Feb 2012

MannKind prices underwritten public offering of 31,250,000 units of common stock

MannKind Corporation today announced the pricing of an underwritten public offering of 31,250,000 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.6 of a share of its common stock.

3 Feb 2012

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.

3 Feb 2012

Sartorius consolidated sales revenue increases to 733.1M for fiscal 2011

Sartorius, a leading international laboratory and process equipment provider, grew dynamically yet again in 2011 and significantly expanded its profitability. Both Group divisions reported highs in sales revenue and earnings.

From Sartorius 2 Feb 2012

Medical Properties Trust prices 20.5M public offering of common stock

Medical Properties Trust, Inc. announced today that it priced its underwritten public offering of 20,500,000 shares of common stock at $9.75 per share.

2 Feb 2012

Prestige acquires 15 brands from GSK

Prestige Brands Holdings, Inc. today announced that it has completed its previously announced purchase of fifteen of the seventeen brands it agreed to acquire from GlaxoSmithKline (GSK).

1 Feb 2012

Omeros, BioMed sign new 15-year lease agreement

BioMed Realty Trust, Inc. announced today the signing of a new 15-year lease with Omeros Corporation for BioMed's Waterfront Research Center property located in Seattle, Washington.

1 Feb 2012

Thermo Fisher fourth quarter revenues increase 15% to $3.13B

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2011.

From Thermo Fisher Scientific Inc. 1 Feb 2012

CartiHeal secures $5M in venture funding

CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced that it raised $5 million in venture funding from two US-Israeli venture capital firms, Accelmed and Access Medical Ventures. The financing will be used to prepare its first product launch early 2013 in Europe.

1 Feb 2012

iRobot announces $6M investment and expanded partnership with InTouch Health

iRobot Corp., a leader in delivering robotic technology-based solutions, today announced a $6 million investment and expanded partnership with InTouch Health, a leading remote presence telemedicine solution provider.

1 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012